Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis

The "Efficacy and Safety of Janus Kinase (JAK1) Selective Inhibitors in the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis" publication uses these data as supplemental information. JAK1-selective inhibitors are widely used as small-molecule targeted agents for the treatment of patients with atopic dermatitis, in this study, we found that JAK1-selective inhibitor monotherapy was more efficacious than the combination, but the incidence of treatment-related adverse effects was subsequently elevated. More data are needed to investigate the efficacy and safety of selective JAK1 inhibitors in the future.

《贾纳斯激酶（Janus Kinase, JAK1）选择性抑制剂治疗特应性皮炎的疗效与安全性：一项系统评价与荟萃分析》一文以本数据集作为补充数据。JAK1选择性抑制剂作为小分子靶向药物，被广泛应用于特应性皮炎患者的临床治疗。本研究显示，JAK1选择性抑制剂单药治疗的疗效优于联合治疗，但治疗相关不良事件的发生率随之升高。未来仍需更多数据以探究JAK1选择性抑制剂的疗效与安全性。